Stephens analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Overweight rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage